At Melanoma Bridge Conference it's the old OMS-100 trial. We will gain more insights into the mechanisms, but the response rates are already known. IMHO not a catalyst.
Edit: see here https://propthink.com/whats-next-for-oncosec-following-premature-melanoma-data/ and esp. the conclusion ("... a market cap of ~$60 million ... about $35M in cash. With early TNBC data in December and updated melanoma data sometime in Q1 2019, we think selling at a panic point is foolish."). Please make your own opinion. The TNBC data is the n=10 sample and the article states that this might only be interesting if some more than the two already known patients received some checkpoint inhibitor therapy (currently we have no hints of this). The update on Pisces (expected by the article in Q1 2019) will be much more, highly relevant.
Besides that there theoretically could be some preclinical results (mouse data) on the next-gen therapy, but usually even these are presented in the context of a medical congress. And I would not call these too much of a catalyst (a little, but not as much as real trial data).
News 
Market Data 
Discover 
